Home — MRC Weatherall Institute of Molecular Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© Adobe Stock

Beyond cancer dependency maps: the PRECISE vision

Dr Sumana Sharma is one of the founding partners of a major new pan-European initiative that aims to transform how scientists identify and target cancer's weaknesses, moving beyond simply mapping cancer vulnerabilities towards predicting them before they are experimentally tested.

Read more

Banner image featuring the words a leader in translating research from bench to clinic, next to an image of a scientist pipetting a pink liquid.

Translating Our Research

Leading research with the aim of improving human health. World-leading research from scientists at the MRC WIMM has been developed into commercial ventures to translate our discoveries into clinics and benefit patients.

Read more

The MRC WIMM Green Impact team with the Gold Green Impact award.

MRC WIMM achieves Gold Green Impact award

Congratulations to the Institute's Green Impact team, who achieved Gold in the University of Oxford's 2026 Green Impact awards.

Read more

Research at the MRC WIMM spans 5 core areas.

© Canva, Science Photo Library

MRC WIMM Research Areas

Research at the MRC WIMM spans 5 core areas.

Read more

The image depicts CAR T cells killing malignant bone marrow cells that are expressing mutant CALR, illustrated as a red ‘flag’ on the cell surface.

© DrawImpacts

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Read more

The MRC WIMM's core mission is to improve human health through the pursuit of fundamental research, the development of new technology, and the translation of discoveries to the clinic.

Discover. Translate. Advance.

The MRC WIMM's core mission is to improve human health through the pursuit of fundamental research, the development of new technology, and the translation of discoveries to the clinic.

Read more

MRC Translational Immune Discovery Unit

Pioneering the future in the study of human immunity to uncover the molecular pathways driving immune-mediated diseases.

Find out more

MRC Molecular Haematology Unit

Understanding how mature blood cells are normally made from stem cells and how this is perturbed in common blood disorders.

Find out more

Centre for Computational Biology

Using computational biology to help understand complex biological systems and combat a range of human diseases.

Find out more

Latest publications

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Sallman DA. et al, (2026), J Clin Oncol

Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention.

Wang L. et al, (2026), Nat Commun

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Huang D. et al, (2026), Cancer Res, 86, 3106 - 3108

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Rampotas A. et al, (2026), Sci Transl Med, 18

TiO2 Alternative Coatings for Ferric Pyrophosphate Premixes: Stability and Bioaccessibility Relative to Ferrous Fumarate

Teichman DL. et al, (2026), Innovative Food Science and Emerging Technologies, 111

More Publications

Upcoming Seminars

Protein-protein interaction networks of leukemia

Tuesday, 01 September 2026, 1pm to 2pm

Speaker(s): Akhihiko Yokoyama

Series: Molecular Haematology Unit

Therapeutic targeting of epigenetic enzymes in haematological malignancies

Tuesday, 22 September 2026, 1pm to 2pm

Speaker(s): Professor Tim Somervaille

Series: Molecular Haematology Unit, WIMM

TBC

Tuesday, 06 October 2026, 1pm to 2pm

Speaker(s): Inigo Martincorena (Wellcome Sanger Institute)

Series: Molecular Haematology Seminar Series

WIMM Seminar - Malignant Transformation of the Immune System and Precision Therapy for Immune Neoplasms

Thursday, 15 October 2026, 12pm to 1pm

Speaker(s): Dr Ari Melnick (Josep Carreras Leukaemia Research Institute Barcelona)

Series: WIMM THURSDAY SEMINARS

More Seminars

MRC WIMM Interactive Timeline

Accessible Version of Timeline